Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/30/2010US7687481 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
03/30/2010US7687480 Phosphonate compounds
03/30/2010US7687479 Characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin
03/30/2010US7687478 for treatment of influenza
03/30/2010US7687477 Polymer solution and dispersion and a process for the preparation thereof
03/30/2010US7687476 administering 4-thiouridine, isomaltitol and uridine as antiinflammatory agents and/or problems in hemostasis related to platelet function
03/30/2010US7687475 RNA interference in respiratory epithelial cells
03/30/2010US7687473 dihydrofolate reductase inhibitors
03/30/2010US7687472 Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders
03/30/2010US7687471 Such as triclabendazole and moxidectin; oral veterinary anthelmintic agents, parasiticides
03/30/2010US7687470 Avermectin and avermectin monosaccharide substituted in the 4″- and 4″ position respectively
03/30/2010US7687469 Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
03/30/2010US7687468 Rejuvenation of stored blood
03/30/2010US7687467 for treatment of attention deficit hyperactivity disorder, narcolepsy; bioavailability
03/30/2010US7687466 Abuse-resistant amphetamine prodrugs
03/30/2010US7687462 gene therapy; neural epidermal growth factor-like 1(NELL)
03/30/2010US7687458 Pharmaceutical compositions of hydrophobic compounds
03/30/2010US7687455 comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy
03/30/2010US7687273 Method for producing purified hematinic iron-saccharidic complex and product produced
03/30/2010US7687249 Polysaccharide derivatives with high antithrombotic activity in plasma
03/30/2010US7687080 Treatment of neuropathy
03/30/2010US7687077 Method to reduce stool odor of companion animals
03/30/2010US7687076 Oxidizing silver nitrate with a persulfate producing a deposition product of silver oxide or Ag2SO4; antimicrobial properties
03/30/2010US7687075 Colonic purgative composition with soluble binding agent
03/30/2010US7687071 acrylic acid-methacrylic acid copolymers; bioavailability
03/30/2010US7687070 Reagents for intracellular delivery of macromolecules
03/30/2010US7687068 Particulate vitamin composition
03/30/2010US7687059 Systems and methods for treating patients with processed lipoaspirate cells
03/30/2010CA2676881A1 Peripheral opioid receptor antagonists and uses thereof
03/30/2010CA2583727C New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives
03/30/2010CA2583437C Novel inhibitors of folic acid-dependent enzymes
03/30/2010CA2577525C Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
03/30/2010CA2572508C One pot synthesis of 2-oxazolidinone derivatives
03/30/2010CA2564990C Morpholine compounds
03/30/2010CA2544963C Myo-inositol hexaphosphate for topical use technical field
03/30/2010CA2537420C Bd crystalline form of ivabradine chlorhydrate, process for the preparation thereof and pharmaceutical compounds containing it
03/30/2010CA2506983C Ca ix-specific inhibitors
03/30/2010CA2496121C Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
03/30/2010CA2495537C Immunoregulatory compounds and derivatives and methods of treating diseases therewith
03/30/2010CA2472237C Multi-stage oral drug controlled-release system
03/30/2010CA2472028C Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
03/30/2010CA2467611C Azithromycin dosage forms with reduced side effects
03/30/2010CA2457444C 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
03/30/2010CA2453312C Therapeutic agent delivery tampon
03/30/2010CA2452920C Benzo [g] quinoline derivatives for treating glaucoma and myopia
03/30/2010CA2450961C Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
03/30/2010CA2445395C Heterocyclic compound and antitumor agent comprising the same as effective component
03/30/2010CA2442245C 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
03/30/2010CA2438651C Mucoadhesive, disintegratable medicinal preparation for active substance administration in veterinary and human medicine
03/30/2010CA2436667C Novel bioactive substance
03/30/2010CA2428184C Thiazolylphenylcarbamoylmethyl amide derivative
03/30/2010CA2424462C Clavulanic acid pharmaceutical compositions
03/30/2010CA2423631C 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
03/30/2010CA2420894C Thienopyrimidines
03/30/2010CA2418084C Substituted and unsubstituted benzooxathiazoles and compounds derived therefrom
03/30/2010CA2412205C Medicinal product package for eradication therapy
03/30/2010CA2409665C Novel composition
03/30/2010CA2405971C New piperazine and piperidine compounds
03/30/2010CA2398898C Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
03/30/2010CA2396049C A health food product comprising a pungent substance
03/30/2010CA2389306C Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
03/30/2010CA2386850C Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
03/30/2010CA2386807C Method of preparing cox-2 inhibitors
03/30/2010CA2380673C Compositions comprising modafinil for treatment of attention deficit hyperactivity disorder
03/30/2010CA2380451C Primary composition containing a lipophilic bioactive compound
03/30/2010CA2378855C Titanium derived compounds, preparation and use thereof
03/30/2010CA2374755C Mono- and disubstituted 3-propyl gamma-aminobutyric acids
03/30/2010CA2364705C Optically pure camptothecin analogues
03/30/2010CA2362277C Spontaneously dispersible n-benzoyl staurosporine compositions
03/30/2010CA2360685C Methods for restoring and/or enhancing accommodation in pseudo phakia
03/30/2010CA2355860C Dosage forms comprising porous particles
03/30/2010CA2306429C Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5t h1a receptors
03/30/2010CA2263765C Methods for the production of protein particles useful for delivery of pharmacological agents
03/30/2010CA2241604C Mesothelium antigen and methods and kits for targeting it
03/30/2010CA2229479C Method of promoting angiogenesis
03/30/2010CA2208780C Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747
03/30/2010CA2193836C Vascular treatment method and apparatus
03/30/2010CA2176183C 3-substituted oxindole derivatives as potassium channel modulators
03/30/2010CA2174652C Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis
03/30/2010CA2144223C Effector proteins of rapamycin
03/25/2010WO2010034011A2 Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
03/25/2010WO2010034003A2 Benzylthiotetrazole inhibitors of store operated calcium release
03/25/2010WO2010033986A2 Dna cytosine deaminase inhibitors
03/25/2010WO2010033981A2 5-azaindole bisphosphonates
03/25/2010WO2010033980A2 4-azaindole bisphosphonates
03/25/2010WO2010033978A2 IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES
03/25/2010WO2010033977A2 Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
03/25/2010WO2010033958A1 Nuclear factor kappa b pathway inhibitor composition and use of same
03/25/2010WO2010033943A1 Biodegradable stent
03/25/2010WO2010033941A1 Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
03/25/2010WO2010033939A1 Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
03/25/2010WO2010033890A1 Polymorphs of 6-beta-naltrexol
03/25/2010WO2010033847A1 Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload
03/25/2010WO2010033832A2 Estriol formulations
03/25/2010WO2010033824A1 Sulfonamide derivatives as inhibitors of ion channels
03/25/2010WO2010033822A2 Therapeutic and diagnostic strategies
03/25/2010WO2010033801A1 Morphinan compounds
03/25/2010WO2010033776A1 Microencapsulation process with solvent and salt
03/25/2010WO2010033771A2 Modulators of hsp70/dnak function and methods of use thereof
03/25/2010WO2010033733A1 Folate receptor binding conjugates of antifolates
1 ... 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 ... 7860